Latest News

• 17 Sep 2020 – Update on Phase 2b clinical study of lead asset XF-73 in the prevention of post-surgical infections
• 17 Sep 2020 – Interim results for the 6 months ended 30 June 2020
• 10 Sep 2020 – Scrip article “Destiny Pharma and SporeGen back Nasal Spray over Vaccine to tackle COVID-19”
• 07 Sep 2020 – Destiny Pharma and SporeGen® announce collaboration and Innovate UK grant award to co-develop novel, preventative treatment for COVID-19
• 17 Aug 2020 – Destiny Pharma welcomes NBIC #BiofilmAware campaign, launched today
• 11 Aug 2020 – Positive interim safety review of Phase 2b clinical trial of lead asset XF-73 in the prevention of post-surgical bacterial infections
• 07 Aug 2020 – Could drug-resistant bacteria cause the next pandemic? – Forbes
• 05 Aug 2020 – Neil Clark, CEO, interviewed by Equity Development
• 27 July 2020 – Update on Phase 2b clinical study of XF-73
• 10 July 2020 – Pharma companies join forces to launch $1 billion fund to develop new antibiotics by 2030